Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concordance between nasopharyngeal swab and bronchoalveolar lavage PCR for respiratory viruses.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

PSEN1 mutant marmoset fibroblasts mimic multi-omic signatures of Alzheimer's disease.

bioRxiv : the preprint server for biology·2026
Same author

Real-world experience using multiplex polymerase chain reaction in intensive care unit patients with hospital-acquired and ventilator-associated pneumonia in South Korea.

Acute and critical care·2026
Same author

Comparison of outcomes of KPC-producing Enterobacterales bloodstream infections treated with ceftazidime-avibactam and other conventional antibiotics: retrospective single-center study.

Microbiology spectrum·2026
Same author

Clinical characteristics and outcomes of adult patients with Hafnia alvei bacteremia in a tertiary care hospital.

Diagnostic microbiology and infectious disease·2026
Same author

Impact of Respiratory Coinfections on Outcomes of Pneumocystis jirovecii Pneumonia in Solid Organ Transplant Recipients.

Transplant infectious disease : an official journal of the Transplantation Society·2026

Related Experiment Video

Updated: May 19, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Ceftazidime for respiratory infections.

Sang-Ho Choi1, Younsuck Koh

  • 1University of Ulsan College of Medicine, Asan Medical Center, Department of Infectious Diseases, Seoul, Republic of Korea.

Expert Opinion on Pharmacotherapy
|September 5, 2012
PubMed
Summary

Ceftazidime remains crucial for hospital-acquired pneumonia (HAP), but rising resistance, particularly in Pseudomonas aeruginosa, compromises its effectiveness. Strategies for optimal ceftazidime use are vital to combat antimicrobial resistance.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

Related Experiment Videos

Last Updated: May 19, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

Area of Science:

  • Infectious Diseases
  • Antimicrobial Resistance
  • Pharmacology

Background:

  • Ceftazidime, a third-generation cephalosporin, exhibits activity against Gram-negative bacilli like Pseudomonas aeruginosa.
  • Increasing antimicrobial resistance and a limited pipeline of new agents necessitate a review of ceftazidime's therapeutic role.

Purpose of the Study:

  • To review in vitro data on ceftazidime's activity against recent clinical isolates.
  • To examine recent randomized controlled trials on ceftazidime's clinical efficacy.
  • To discuss strategies for optimizing ceftazidime use in treating hospital-acquired pneumonia (HAP).

Main Methods:

  • Literature review of in vitro studies on ceftazidime's antibacterial activity.
  • Analysis of recent randomized controlled trials evaluating ceftazidime's clinical efficacy.
  • Synthesis of data to inform optimal treatment strategies for HAP.

Main Results:

  • Ceftazidime's efficacy in HAP treatment is challenged by increased resistance rates over the past decade.
  • Pseudomonas aeruginosa and Acinetobacter baumannii show significant resistance to ceftazidime.
  • Ceftazidime remains an important option, but its utility is diminishing due to resistance.

Conclusions:

  • Understanding local resistance patterns is crucial for effective ceftazidime use in severe HAP.
  • Reserve ceftazidime for susceptible pathogens and consider optimized administration (prolonged/continuous infusion).
  • Investigate ceftazidime combinations with beta-lactamase inhibitors and tailor therapy to individual patient needs to combat resistance.